News
New Amsterdam Sciences Announces Pre-IND Phase 2 Submission with FDA Coronavirus Treatment Acceleration Program for NAS150 Targeting the Omicron Variant and all variants of SARS-CoV-2
NAS Proposes Phase 2 Clinical Stage Agent Can Be an Effective Treatment and Adjuvant Therapeutic for COVID-19. NAS150 Application Could Also Potentially Be Applied for COVID-19 Central Nervous System Conditions specifically those related to “Long Haul” conditions. Scottsdale, Arizona, December 3rd 2021 – New Amsterdam Sciences, a privately held Read more…